1.69

2.87% -0.05

Annovis Bio Inc (ANVS)

Panoramica Notizia Cronologia dei prezzi Perché ANVS Giù? Forum Previsione

Precedente Chiudi:

$1.74

Aprire:

$1.7

Volume 24 ore:

620.10K

Relative Volume:

0.58

Capitalizzazione di mercato:

$71.90M

Reddito:

Utile/perdita netta:

$-40.92M

Rapporto P/E:

-0.9844

EPS:

-1.7167

Flusso di cassa netto:

$-26.53M

1 W Prestazione:

-3.98%

1M Prestazione:

-3.43%

6M Prestazione:

-39.43%

1 anno Prestazione:

-36.23%

Intervallo 1D:

$1.66

$1.74

Intervallo di 1 settimana:

$1.66

$1.825

Portata 52W:

$1.5407

$5.50

Annovis Bio Inc Stock (ANVS) Company Profile

Nome

Annovis Bio Inc

Settore

Healthcare (1089)

Industria

Biotechnology (603)

Telefono

484-875-3192

Indirizzo

101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-11

Ultimi documenti SEC

ANVS's Discussions on Twitter

Compare ANVS vs VRTX, REGN, ARGX, RVMD, ALNY

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ANVS Annovis Bio Inc	1.69	71.90M	0	-40.92M	-26.53M	-1.7167
VRTX Vertex Pharmaceuticals Inc	480.50	121.95B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.15	70.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.19	52.94B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	180.39	38.35B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	272.67	36.40B	4.29B	577.22M	641.34M	4.2086

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-10	Downgrade	D. Boral Capital	Buy → Hold
2024-10-25	Aggiornamento	Maxim Group	Hold → Buy
2023-12-29	Iniziato	Canaccord Genuity	Buy
2021-07-07	Reiterato	Maxim Group	Buy

Annovis Bio Inc Borsa (ANVS) Ultime notizie

Jul 13, 2026

Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial - MyChesCo

Jul 13, 2026

Jul 10, 2026

Annovis Bio enrolls over 850 patients for its next Alzheimer's Disease trial - qz.com

Jul 10, 2026

Annovis Bio Completes Enrollment for Pivotal Phase 3 Alzheimer’s Trial, Plans NDA Submissions in 2027 and 2028 12 - Minichart

Jul 10, 2026

Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial - TipRanks

Jul 10, 2026

Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled - TradingView

Jul 10, 2026

Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan

Jul 10, 2026

Jul 09, 2026

Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Jul 09, 2026

Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS) - The Globe and Mail

Jul 09, 2026

Jul 08, 2026

Annovis Promotes Research Chief as Lead Drug Nears Key Trial - MyChesCo

Jul 08, 2026

Jul 07, 2026

Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial - Yahoo Finance

Jul 07, 2026

The timeline for the key clinical trial data readout of Annovis Bio Inc. has been clarified. - Bitget

Jul 07, 2026

Annovis Bio completes enrollment in phase 3 Alzheimer’s trial By Investing.com - Investing.com Australia

Jul 07, 2026

Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease - Moomoo

Jul 07, 2026

Annovis Bio completes enrollment in phase 3 Alzheimer’s trial - Investing.com

Jul 07, 2026

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire

Jul 07, 2026

Jul 04, 2026

The buntanetap programAnnovis Bio bets on neurodegeneration trials - ad-hoc-news.de

Jul 04, 2026

Jul 01, 2026

Annovis Bio promotes Cheng Fang to chief scientific officer By Investing.com - Investing.com Australia

Jul 01, 2026

Annovis Bio promotes Cheng Fang to chief scientific officer - Investing.com

Jul 01, 2026

Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones - citybiz

Jul 01, 2026

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - The Manila Times

Jul 01, 2026

Press Release: Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - Moomoo

Jul 01, 2026

Jun 30, 2026

ANVSAnnovis Bio Inc Latest SEC Filings - Finviz

Jun 30, 2026

Jun 29, 2026

ANVS Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineAnalyst Consensus Shift - dars.gov.et

Jun 29, 2026

Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

ANVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 28, 2026

Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Annovis Bio (ANVS) Shows Resilience With 4.24% Gain, Testing Key ResistanceBeta Neutral Pair - dars.gov.et

Jun 27, 2026

Annovis Bio | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Jun 27, 2026

Jun 26, 2026

Enterprise value to EBITDA forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView

Jun 25, 2026

Price to sales forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView

Jun 25, 2026

Enterprise value to revenue forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView

Jun 25, 2026

Jun 24, 2026

Annovis Bio Q1 2026 Earnings: EPS Misses Wide Expectations as Pre-Revenue Biotech Advances PipelineLow Growth Earnings - DonanımHaber

Jun 24, 2026

Jun 21, 2026